HitGen Inc. (SHA: 688222) announced that its wholly‑owned Hong Kong subsidiary, HitGen (HK) Ltd., together with OrbiMed Asia Partners, LAV, Panku Capital Limited, and other investors, has jointly invested in Connexus Therapeutics, an innovative‑drug company focused on novel small‑molecule oncology therapeutics, with its entire pipeline currently at the preclinical research stage.
Deal Snapshot
| Item | Detail |
|---|---|
| Investors | HitGen (HK) Ltd., OrbiMed Asia Partners, LAV, Panku Capital Limited, and other investors |
| Target Company | Connexus Therapeutics |
| Financing Round | Series A, completed concurrently with the joint investment |
| Therapeutic Focus | Novel small‑molecule drugs in oncology |
| Pipeline Stage | All projects at preclinical research stage |
| HitGen Role | Founding shareholder via HitGen (HK) Ltd.; founding equity acquired through a phased technology licensing arrangement |
| Deal Value | Not disclosed |
| Announcement Date | 17 Sep 2026 |
Deal Structure & Governance
- Founding Equity via Technology Licensing: Under the agreement, HitGen will acquire founding equity in Connexus through a phased technology licensing arrangement – converting its discovery‑platform expertise into an ownership position rather than a conventional cash‑only stake.
- Independent Operations: Connexus will build its own team to operate independently and undertake the subsequent development of the drug projects.
- Concurrent Series A: Connexus completed its Series A financing in this round, with funding support from investors including OrbiMed Asia Partners.
- Collaboration Framework: All parties will leverage their respective strengths to jointly advance development of the drug projects and explore subsequent pathways for global collaboration and value realization.
Strategic Context & Market Impact
- Platform Monetization Model: The structure exemplifies HitGen’s strategy of converting its DNA‑encoded compound library (DEL)–based drug discovery capability into equity upside at portfolio companies, supplementing fee‑for‑service and partnership income streams.
- Blue‑Chip Investor Validation: Participation by OrbiMed Asia Partners – one of healthcare’s most prominent specialist investors – alongside LAV and Panku Capital provides both capital and strategic credibility to a preclinical‑stage startup.
- Oncology Small‑Molecule Focus: Connexus enters a competitive small‑molecule oncology landscape where differentiated chemistry and modality innovation are key value drivers; specific targets, programs, and preclinical data were Not disclosed.
- Exit Pathways: The stated intent to explore global collaboration and value realization signals potential future out‑licensing, partnership, or financing milestones as programs advance into the clinic.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the investment in Connexus Therapeutics, pipeline development, technology licensing arrangements, and potential global collaboration and value‑realization pathways. Actual results may differ materially due to risks including preclinical development outcomes, regulatory pathways, financing conditions, and competitive dynamics. All Connexus programs are preclinical and no product has received any marketing authorization.-Fineline Info & Tech
